We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome.
- Authors
Singh, Jasraj; Adel, Fadi W.; Scott, Christopher G.; Chen, Horng H.
- Abstract
Aims: Define the relationship between N‐terminal atrial natriuretic peptide (NT‐ANP) levels and incident metabolic syndrome and type 2 diabetes mellitus ('metabolic disease') in healthy adults and develop a risk prediction score. Materials and Methods: Retrospective cohort study of Olmsted County Heart Function Study participants, a random sampling of county residents aged 45 years and older (n = 2042). Clinical data were collected during enrolment between 1997 and 2000 and upon follow‐up 4 years later. Outcomes were followed for 8 years. We studied 715 subjects without metabolic disease at enrolment who completed follow‐up, assessing incident metabolic disease as the primary outcome. Youden's index was used to identify optimal cut‐points and develop the risk score. Results: Upon multivariate analysis adjusting for age gender, HDL and triglycerides, higher baseline serum NT‐ANP levels were associated with a lower risk of metabolic disease (OR: 0.65, CI 0.49–0.85, p = 0.002). Higher baseline serum insulin and aldosterone levels were associated with higher risk of incident metabolic disease (OR: 2.04, CI 1.57–2.65, p < 0.001; OR: 1.43, CI 1.14–1.81, p = 0.002, respectively). Baseline serum NT‐ANP < 3337 pg/mL was 96.6% sensitive for future development of metabolic disease. A weighted score including all three biomarkers was 78.6% sensitive and 77.3% specific. Conclusions: In healthy adults aged 45 years or older, higher baseline NT‐ANP levels are associated with a lower four‐year risk of developing metabolic disease. Serum NT‐ANP levels are a sensitive biomarker of future risk of metabolic disease and have screening utility when combined with insulin and aldosterone levels into a composite score.
- Subjects
ATRIAL natriuretic peptides; TYPE 2 diabetes; DISEASE risk factors; METABOLIC disorders; METABOLIC syndrome
- Publication
Diabetes, Obesity & Metabolism, 2025, Vol 27, Issue 2, p777
- ISSN
1462-8902
- Publication type
Academic Journal
- DOI
10.1111/dom.16073